Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.
Australian Clinical Labs Ltd announced the issuance and conversion of unquoted equity securities, specifically 59,046 ordinary fully paid shares, as part of its ongoing financial operations. This move reflects the company’s strategic efforts to manage its equity structure, potentially impacting its market positioning and offering implications for its stakeholders.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, primarily focusing on providing pathology services. The company is known for its comprehensive range of diagnostic services, catering to both individual patients and medical practitioners across Australia.
Average Trading Volume: 927,021
Technical Sentiment Signal: Sell
Current Market Cap: A$536.1M
Find detailed analytics on ACL stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue